Annual Cash & Cash Equivalents
$38.63 M
+$31.73 M+459.74%
December 31, 2023
Summary
- As of February 8, 2025, XLO annual cash & cash equivalents is $38.63 million, with the most recent change of +$31.73 million (+459.74%) on December 31, 2023.
- During the last 3 years, XLO annual cash & cash equivalents has risen by +$32.58 million (+539.28%).
- XLO annual cash & cash equivalents is now at all-time high.
Performance
XLO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$61.26 M
-$13.69 M-18.27%
September 30, 2024
Summary
- As of February 8, 2025, XLO quarterly cash and cash equivalents is $61.26 million, with the most recent change of -$13.69 million (-18.27%) on September 30, 2024.
- Over the past year, XLO quarterly cash and cash equivalents has increased by +$16.55 million (+37.03%).
- XLO quarterly cash and cash equivalents is now -69.07% below its all-time high of $198.05 million, reached on December 31, 2021.
Performance
XLO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
XLO Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +459.7% | +37.0% |
| 3 y3 years | +539.3% | +37.0% |
| 5 y5 years | +4359.9% | +37.0% |
XLO Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +465.7% | -69.1% | +80.3% |
| 5 y | 5-year | at high | +905.9% | -69.1% | +218.4% |
| alltime | all time | at high | +4359.9% | -69.1% | +218.4% |
Xilio Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $61.26 M(-18.3%) |
| Jun 2024 | - | $74.95 M(+120.6%) |
| Mar 2024 | - | $33.98 M(-24.0%) |
| Dec 2023 | $38.63 M(+459.7%) | $44.70 M(-25.2%) |
| Sep 2023 | - | $59.77 M(-20.7%) |
| Jun 2023 | - | $75.38 M(-19.2%) |
| Mar 2023 | - | $93.27 M(-22.5%) |
| Dec 2022 | $6.90 M | $120.39 M(-13.5%) |
| Sep 2022 | - | $139.14 M(-12.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $159.41 M(-9.9%) |
| Mar 2022 | - | $176.96 M(-10.7%) |
| Dec 2021 | $6.83 M(+13.0%) | $198.05 M(+98.5%) |
| Sep 2021 | - | $99.77 M(-17.1%) |
| Jun 2021 | - | $120.30 M(+525.3%) |
| Dec 2020 | $6.04 M(+57.4%) | $19.24 M |
| Dec 2019 | $3.84 M(+343.4%) | - |
| Dec 2018 | $866.10 K(-53.0%) | - |
| Dec 2017 | $1.84 M(-27.1%) | - |
| Dec 2016 | $2.53 M | - |
FAQ
- What is Xilio Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Xilio Therapeutics?
- What is Xilio Therapeutics annual cash & cash equivalents year-on-year change?
- What is Xilio Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Xilio Therapeutics?
- What is Xilio Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Xilio Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of XLO is $38.63 M
What is the all time high annual cash & cash equivalents for Xilio Therapeutics?
Xilio Therapeutics all-time high annual cash & cash equivalents is $38.63 M
What is Xilio Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, XLO annual cash & cash equivalents has changed by +$31.73 M (+459.74%)
What is Xilio Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of XLO is $61.26 M
What is the all time high quarterly cash and cash equivalents for Xilio Therapeutics?
Xilio Therapeutics all-time high quarterly cash and cash equivalents is $198.05 M
What is Xilio Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, XLO quarterly cash and cash equivalents has changed by +$16.55 M (+37.03%)